GIP and type 2 diabetes mellitus: The SURPASS-CVOT (comparison of Tirzepatide and Dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease) is an ongoing trial aiming to assess for any additional cardiovascular outcome benefits over and above current standard treatment with GIP/GLP-1 receptor agonists (119).